Assessing the Age Specificity of Infection Fatality Rates for Covid-19: Systematic Review, Meta-Analysis, & Public Policy Implications
暂无分享,去创建一个
[1] N. Akilli,et al. Prevalence of Asymptomatic SARS-CoV-2 Infection , 2021, Annals of Internal Medicine.
[2] G. Chertow,et al. Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study , 2020, The Lancet.
[3] A. Giacomelli,et al. Seroprevalence of SARS-CoV-2 significantly varies with age: Preliminary results from a mass population screening , 2020, Journal of Infection.
[4] H. Kamel,et al. Seroprevalence of Antibodies to SARS-CoV-2 in US Blood Donors , 2020, medRxiv.
[5] A. Trkola,et al. Variation in SARS-CoV-2 seroprevalence in school-children across districts, schools and classes , 2020, medRxiv.
[6] S. Stramer,et al. Change in Donor Characteristics and Antibodies to SARS-CoV-2 in Donated Blood in the US, June-August 2020. , 2020, JAMA.
[7] P. Myles,et al. A dual antigen ELISA allows the assessment of SARS-CoV-2 antibody seroprevalence in a low transmission setting , 2020, medRxiv.
[8] S. Rigatti,et al. SARS-CoV-2 Antibody Prevalence and Association with Routine Laboratory Values in a Life Insurance Applicant Population , 2020, medRxiv.
[9] Christina C. Chang,et al. High Seroprevalence of Anti-SARS-CoV-2 Antibodies in Chelsea, Massachusetts , 2020, The Journal of infectious diseases.
[10] Jan,et al. Risk Factors for COVID-19: Community Exposure and Mask-Wearing , 2020, SSRN Electronic Journal.
[11] S. Ladhani,et al. Seroprevalence of SARS-CoV-2 antibodies in children: a prospective multicentre cohort study , 2020, Archives of Disease in Childhood.
[12] C. Yiannoutsos,et al. Infection Fatality Ratios for COVID-19 Among Noninstitutionalized Persons 12 and Older: Results of a Random-Sample Prevalence Study , 2020, Annals of Internal Medicine.
[13] A. Gylfason,et al. Humoral Immune Response to SARS-CoV-2 in Iceland , 2020, The New England journal of medicine.
[14] P. Katzmarzyk,et al. Racial and workplace disparities in seroprevalence of SARS-CoV-2 in Baton Rouge, Louisiana, July 15-31, 2020 , 2020, medRxiv.
[15] G. Kochs,et al. Prevalence of SARS-CoV-2 Infection in Children and Their Parents in Southwest Germany , 2020, JAMA pediatrics.
[16] M. Breteler,et al. Seroprevalence and correlates of SARS-CoV-2 neutralizing antibodies: Results from a population-based study in Bonn, Germany , 2020, medRxiv.
[17] D. Cummings,et al. Age-specific mortality and immunity patterns of SARS-CoV-2 infection in 45 countries , 2020, medRxiv.
[18] M. Ranjan,et al. High SARS-CoV-2 Seroprevalence in Children and Adults in the Austrian Ski Resort Ischgl , 2020, medRxiv.
[19] M. Peluso,et al. Universal PCR and antibody testing demonstrate little to no transmission of SARS-CoV-2 in a rural community , 2020, medRxiv.
[20] M. Dake,et al. Detection, prevalence, and duration of humoral responses to SARS-CoV-2 under conditions of limited population exposure , 2020, medRxiv.
[21] C. Donnelly,et al. Antibody prevalence for SARS-CoV-2 in England following first peak of the pandemic: REACT2 study in 100,000 adults , 2020, medRxiv.
[22] Jose L. Paniagua,et al. SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study , 2020, medRxiv.
[23] A. Ko,et al. Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study , 2020, medRxiv.
[24] D. Buckeridge,et al. SeroTracker: a global SARS-CoV-2 seroprevalence dashboard , 2020, The Lancet Infectious Diseases.
[25] S. Merler,et al. Age-specific SARS-CoV-2 infection fatality ratio and associated risk factors, Italy, February to April 2020 , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[26] E. Petinaki,et al. Repeated leftover serosurvey of SARS-CoV-2 IgG antibodies, Greece, March and April 2020 , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[27] C. Steves,et al. Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England , 2020, Journal of Infection.
[28] E. Price-Haywood,et al. Seroprevalence of SARS-CoV-2 and Infection Fatality Ratio, Orleans and Jefferson Parishes, Louisiana, USA, May 2020 , 2020, Emerging infectious diseases.
[29] P. Kelleher,et al. High Prevalence of Asymptomatic COVID-19 Infection in Hemodialysis Patients Detected Using Serologic Screening. , 2020, Journal of the American Society of Nephrology : JASN.
[30] Jungsang Ryou,et al. Seroprevalence of Anti-SARS-CoV-2 Antibodies among Outpatients in Southwestern Seoul, Korea , 2020, Journal of Korean medical science.
[31] Daniel J. Nesbitt,et al. Low Seroprevalence of SARS-CoV-2 in Rhode Island Blood Donors Determined using Multiple Serological Assay Formats , 2020, medRxiv.
[32] T. Fujiwara,et al. Seroprevalence of SARS-CoV-2 IgG Antibodies in Utsunomiya City, Greater Tokyo, after first pandemic in 2020 (U-CORONA): a household- and population-based study , 2020, medRxiv.
[33] Brian E. Dixon,et al. Population Point Prevalence of SARS-CoV-2 Infection Based on a Statewide Random Sample — Indiana, April 25–29, 2020 , 2020, MMWR. Morbidity and mortality weekly report.
[34] Nicholas P. Deputy,et al. Estimated Community Seroprevalence of SARS-CoV-2 Antibodies — Two Georgia Counties, April 28–May 3, 2020 , 2020, MMWR. Morbidity and mortality weekly report.
[35] R. Walensky,et al. Serosurveillance and the COVID-19 Epidemic in the US: Undetected, Uncertain, and Out of Control. , 2020, JAMA.
[36] Kathryn T. Morrison,et al. High Community SARS-CoV-2 Antibody Seroprevalence in a Ski Resort Community, Blaine County, Idaho, US. Preliminary Results , 2020, medRxiv.
[37] E. Berényi,et al. Novel coronavirus epidemic in the Hungarian population, a cross-sectional nationwide survey to support the exit policy in Hungary , 2020, GeroScience.
[38] A. Scherag,et al. Seroprevalence of SARS-CoV-2 antibodies in an entirely PCR-sampled and quarantined community after a COVID-19 outbreak - the CoNAN study , 2020, medRxiv.
[39] A. Dalpke,et al. Anti-SARS-CoV-2 IgG antibodies in adolescent students and their teachers in Saxony, Germany (SchoolCoviDD19): very low seropraevalence and transmission rates , 2020, medRxiv.
[40] D. Lee,et al. IgG Seroprevalence of COVID-19 among Individuals without a History of the Coronavirus Disease Infection in Daegu, Korea , 2020, Journal of Korean medical science.
[41] D. Skowronski,et al. Low SARS-CoV-2 sero-prevalence based on anonymized residual sero-survey before and after first wave measures in British Columbia, Canada, March-May 2020 , 2020, medRxiv.
[42] P. Glasziou,et al. Estimating the seroprevalence of SARS-CoV-2 infections: systematic review , 2020, medRxiv.
[43] J. Izopet,et al. The real seroprevalence of SARS-CoV-2 in France and its consequences for virus dynamics , 2020, Scientific Reports.
[44] M. Hernán,et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study , 2020, The Lancet.
[45] Kana Yamamoto,et al. Geographical Profiles of COVID-19 Outbreak in Tokyo: An Analysis of the Primary Care Clinic–Based Point-of-Care Antibody Testing , 2020, Journal of primary care & community health.
[46] C. Knabbe,et al. SARS-CoV-2 IgG seroprevalence in blood donors located in three different federal states, Germany, March to June 2020 , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[47] H. V. Bakel,et al. Seroconversion of a city: Longitudinal monitoring of SARS-CoV-2 seroprevalence in New York City , 2020, medRxiv.
[48] C. Reed,et al. Seroprevalence of Antibodies to SARS-CoV-2 in Six Sites in the United States, March 23-May 3, 2020 , 2020, medRxiv.
[49] A. Giacomelli,et al. Seroprevalence of SARS-CoV-2 IgG significantly varies with age: results from a mass population screening (SARS-2-SCREEN-CdA). , 2020, medRxiv.
[50] S. Lee,et al. Antibody Responses to SARS-CoV-2 at 8 Weeks Postinfection in Asymptomatic Patients , 2020, Emerging infectious diseases.
[51] Christel Faes,et al. Belgian Covid-19 Mortality, Excess Deaths, Number of Deaths per Million, and Infection Fatality Rates (8 March - 9 May 2020) , 2020, medRxiv.
[52] M. Margaglione,et al. FAR AWAY FROM HERD IMMUNITY TO SARS-CoV-2: results from a survey in healthy blood donors in South Eastern Italy , 2020, medRxiv.
[53] S. Lauer,et al. Serology-informed estimates of SARS-COV-2 infection fatality risk in Geneva, Switzerland , 2020, medRxiv.
[54] A. Flahault,et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study , 2020, The Lancet.
[55] A. von Eckardstein,et al. Population-wide evolution of SARS-CoV-2 immunity tracked by a ternary immunoassay , 2020, medRxiv.
[56] T. Matsumura,et al. Challenges of community point-of-care antibody testing for COVID-19 herd-immunity in Japan , 2020, QJM : monthly journal of the Association of Physicians.
[57] J. Núñez,et al. The Effect of Age on Mortality in Patients With COVID-19: A Meta-Analysis With 611,583 Subjects , 2020, Journal of the American Medical Directors Association.
[58] S. Ciesek,et al. Epidemiological study to detect active SARS-CoV-2 infections and seropositive persons in a selected cohort of employees in the Frankfurt am Main metropolitan area , 2020, medRxiv.
[59] P. Horby,et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study , 2020, BMJ.
[60] Kristen M J Azar,et al. Disparities In Outcomes Among COVID-19 Patients In A Large Health Care System In California. , 2020, Health affairs.
[61] J. Ioannidis,et al. The infection fatality rate of COVID-19 inferred from seroprevalence data , 2020, medRxiv.
[62] R. Krüger,et al. Prevalence of SARS-CoV-2 infection in the Luxembourgish population: the CON-VINCE study. , 2020, medRxiv.
[63] S. Bosari,et al. SARS-CoV-2 seroprevalence trends in healthy blood donors during the COVID-19 Milan outbreak , 2020, medRxiv.
[64] M. Nöthen,et al. Infection fatality rate of SARS-CoV-2 infection in a German community with a super-spreading event , 2020 .
[65] M. Wener,et al. Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in Boise, Idaho , 2020, Journal of Clinical Microbiology.
[66] Akihide Ryo,et al. Interpreting Diagnostic Tests for SARS-CoV-2. , 2020, JAMA.
[67] G. Meyerowitz-Katz,et al. A systematic review and meta-analysis of published research data on COVID-19 infection fatality rates , 2020, International Journal of Infectious Diseases.
[68] K. Iwata,et al. Estimation of seroprevalence of novel coronavirus disease (COVID-19) using preserved serum at an outpatient setting in Kobe, Japan: A cross-sectional study , 2020, Clinical Epidemiology and Global Health.
[69] Simon J. More,et al. Inferred duration of infectious period of SARS-CoV-2: rapid scoping review and analysis of available evidence for asymptomatic and symptomatic COVID-19 cases , 2020, BMJ Open.
[70] C. Reusken,et al. Herd immunity is not a realistic exit strategy during a COVID-19 outbreak , 2020 .
[71] X. Tang,et al. Antibody responses to SARS-CoV-2 in patients with COVID-19 , 2020, Nature Medicine.
[72] Jens K. Boldsen,et al. Estimation of SARS-CoV-2 Infection Fatality Rate by Real-time Antibody Screening of Blood Donors , 2020, medRxiv.
[73] Eun Ji Kim,et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. , 2020, JAMA.
[74] D. Larremore,et al. Estimating SARS-CoV-2 seroprevalence and epidemiological parameters with uncertainty from serological surveys , 2020, medRxiv.
[75] E. Lavezzo,et al. Suppression of COVID-19 outbreak in the municipality of Vo, Italy , 2020, medRxiv.
[76] P. Gallian,et al. Cluster of COVID-19 in northern France: A retrospective closed cohort study , 2020, medRxiv.
[77] J. Ioannidis,et al. COVID-19 antibody seroprevalence in Santa Clara County, California , 2020, medRxiv.
[78] Jordan J. Clark,et al. Detection of neutralising antibodies to SARS-CoV-2 to determine population exposure in Scottish blood donors between March and May 2020 , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[79] Kari Stefansson,et al. Spread of SARS-CoV-2 in the Icelandic Population , 2020, The New England journal of medicine.
[80] A. Mirzazadeh,et al. Epidemiological characteristics of COVID-19: a systematic review and meta-analysis , 2020, Epidemiology and Infection.
[81] Francesca Molinari,et al. Estimating the COVID-19 infection rate: Anatomy of an inference problem , 2020, Journal of Econometrics.
[82] Christl A. Donnelly,et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis , 2020, The Lancet Infectious Diseases.
[83] G. Chowell,et al. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020 , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[84] Hiroshi Nishiura,et al. The Rate of Underascertainment of Novel Coronavirus (2019-nCoV) Infection: Estimation Using Japanese Passengers Data on Evacuation Flights , 2020, Journal of clinical medicine.
[85] Andrea Benedetti,et al. Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis , 2020, BMJ.
[86] Å. Lundkvist,et al. Pronounced difference in Covid-19 antibody prevalence indicates cluster transmission in Stockholm, Sweden , 2020, Infection ecology & epidemiology.
[87] R. Magalhães,et al. Heterogeneous and Dynamic Prevalence of Asymptomatic Influenza Virus Infections , 2016, Emerging infectious diseases.
[88] S. Lattimore,et al. Blood donors in England and North Wales: demography and patterns of donation , 2015, Transfusion.
[89] David J Spiegelhalter,et al. A re-evaluation of random-effects meta-analysis , 2009, Journal of the Royal Statistical Society. Series A,.
[90] J. Higgins,et al. Meta-Regression in Stata , 2008 .
[91] Ruth B. Greenberg,et al. University of Louisville School of Medicine , 2004, Academic medicine : journal of the Association of American Medical Colleges.
[92] F. Eugene Yates,et al. The national center for health statistics , 1973, Annals of Biomedical Engineering.
[93] D. Moher,et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.
[94] N. Crepaz,et al. Higher incidence of clear cell adenocarcinoma of the cervix and vagina among women born between 1947 and 1971 in the United States , 2011, Cancer Causes & Control.
[95] P. Tüll,et al. European Centre for Disease Prevention and Control , 2006 .
[96] S. Haeghebaert,et al. BULLETIN EUROPÉEN SUR LES MALADIES TRANSMISSIBLES / EUROPEAN COMMUNICABLE DISEASE BULLETIN , 2003 .
[97] T. Taufa,et al. Health statistics. , 1986, Papua and New Guinea medical journal.
[98] B. Gladen,et al. Estimating prevalence from the results of a screening test. , 1978, American journal of epidemiology.